Zusammenfassung
Die insgesamt ungünstige Prognose von Patienten mit Magen- oder Ösophaguskarzinom hat sich in den letzten Jahrzehnten nicht entscheidend gebessert, obwohl die Rate an Ro-Resektonen höher geworden ist und die perioperative Mortalität erheblich gesenkt werden konnte. Die Tatsache, dass in der Mehrzahl der Fälle eine Tumorausbreitung über die Organgrenzen hinaus erfolgt, die mit alleinigen Lokalmaßnahmen nicht kontrollierbar ist, unterstreicht die Notwendigkeit für systemisch wirksame Therapien. Hier steht uns derzeit nur die Chemotherapie als die einzige in ihrer Wirksamkeit belegte Behandlungsmaßnahme zur Verfügung.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Ajani JA, Van Cutsem E, Moiseyenko V et al. (2003) Docetaxel (D), cisplatin, 5-fluorouracil compared to cisplatin (C) and 5-fluorouracil (F) for chemo-naíve patients with metastatic or locally recurrent, unresectable gastric karzinoma (MGC): interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 22: (Abstract 999)
Bouche O, Raoul JL, Giovanni M et al. (2003) Randomized phase II trial of LV5FU2, LV5FU2-cisplatinum of LV5FU2-irinotecan in patients (pts) with metastatic gastric orcardial adenocarcinoma (MGA): final results of study FFCD 9803. Proc Am Soc Clin Oncol 22: (Abstract 1033)
Cervantes M, Navarro A, Carrato J et al. (1999) The addition of cisplatin to continuous infusion 5-fluorouracil for the treatment of advanced gastric cancer. Results of two consecutive phase II trials of the Spanish Group for Gastrointestinal Tumor Terapy (TTD). Proc Am Soc Clin Oncol 18: (Abstract 980)
Edelman MJ (2000) Recent developments in the chemotherapy of advanced esophageal cancer. Chest Surg North Am 10:561–567
Enzinger PC, Ilson DH, Kelsen DP (1999) Chemotherapy in Esophageal cancer. Semin Oncol 26:12–20
Ilson DH, Saltz L, Enzinger P et al. (1999) Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17: 3270–3275
Kok TC (1997) Chemotherapy in oesophageal cancer. Cancer Treat Rev 23:65–85
Mitry E, Artru P, Taieb J et al. (2000) Combination of leucovorin, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in the treatment of advanced upper gastrointestinal carcinomas (AUGIC). Ann Oncol 11(Suppl 4): 65 (Abstract 286 P)
Moehler MH, Siebler J, Hoehler T et al. (2003) Safety and efficacy of CPT-11/FA/5-FU (ILF) vs. ELF in previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, Proc Am Soc Clin Oncol 22: (Abstract 1034)
Preusser P, Achterrath W, Wilke H et al. (1988) Chemotherapy of gastric cancer. Cancer Treat Rev 15:257–277
Preusser P, Achterrath W, Wilke H et al. (1990) Chemotherapie des Ösophaguskarzinoms. In:Langhans P, Schreiber HW, Häring R, Reding R, Siewert JR, Bünte H (Hrsg) Aktuelle Therapie des Ösophaguskarzinoms. Springer, Berlin Heidelberg New York Tokio, S 298–309
Sumpter KA, Harper-Wynne C, Cunningham D et al. (2003) Randomised, multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: confirmation of dose escalation. Proc Am Soc Clin Oncol 22: (Abstract 1031)
Vanhoefer U, Rougier P, Wilke H et al. (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin vs. etoposide, leucovorin, and fluorouracil vs. infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18/14:2648–2467
Vanhoefer U, Rougier P, Wilke H et al. (2002) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin vs. etoposide, leucovorin, and fluorouracil vs. infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol (Classic Papers Current Comments). Gastrointest Cancer 6/4: 761–771
Webb A, Cunningham D, Scarffe JH et al. (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil vs. fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.J Clin Oncol 15/1:261–267
Wilke H, Korn M, Köhne C et al. (1996) Phase II results of weekly infusional high-dose FU (HD-FU) plus folinic acid (FA) and biweekly cisplatin (C) for advanced gastric cancer. Ann Oncol 7(Suppl 5): 46 (Abstract 213 O)
Wilke H, Van Cutsem E (2003) Current treatments and future perspectives in colorectal and gastric cancer. Ann Oncol (Suppl 2) 14: 1149–1155
Wilke H, Wils, J, Stahl M (2003) Chemotherapy of gastric cancer (advanced and adjuvant). In: Markman M (ed) Atlas of cancer. Lippincott, Williams & Williams, Philadelphia, pp 208–214
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Preusser, P., Achterrath, W., Stahl, M., Berns, T., Wilke, H. (2004). Palliative Chemotherapie des Magen-und Ösophaguskarzinoms. In: Management des Magen- und Ösophaguskarzinoms. Onkologie aktuell. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18700-1_41
Download citation
DOI: https://doi.org/10.1007/978-3-642-18700-1_41
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62254-0
Online ISBN: 978-3-642-18700-1
eBook Packages: Springer Book Archive